Data from the Centers for Disease Control and Prevention (CDC) indicates that more than 42% of adults in the country are living with obesity, which is creating a large treatment-eligible population for incretin-based therapies
Already, GLP-1 weight loss prescriptions Wegovy, Rybelsus and Saxendaalong with Ozempicare the single biggest driver of employer health costs, adding 1% to the total premium expense for 2025, data released last fall from the benefits consultancy Aon said
By this point, you should be on the highest Mounjaro dose, which has the greatest potential for weight loss
GHK-Cu steps in by signaling the cells responsible for creating this framework, called fibroblasts, to get back to work
In addition to medication management, we offer a range of services, including primary care, chronic disease management, preventive care, and wellness programs
Blood-brain barrier transport of therapeutics via receptor-mediation